OncLive SOSS

Authors

Jonathan Ticku, MD

Latest:

Cloud Computing for Fellows

Cloud computing refers to Web-based programs that allow the user to store information in a central location, typically not the device being used to access the information (such as your laptop, desktop PC, or iPad).

Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Latest:

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Jonathan Tward, MD, PhD

Latest:

Dr. Tward on Abbreviated Course ADT for Prostate Cancer

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

Jonathan W. Friedberg, MD, MMSc

Latest:

Rituximab Sets the Pace in Changing Lymphoma Landscape

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

Jonathan W. Friedberg, MD, University of Rochester

Jonathan W. Goldman, MD

Latest:

Dr. Goldman on Key Takeaways From the CASPIAN Trial in Frontline ES-SCLC

Jonathan W. Goldman, MD, discusses key takeaways from the phase 3 CASPIAN trial in patients with extensive-stage small cell lung cancer.

Jonathan W. Riess, MD, MS, UC Davis Comprehensive Cancer Center

Latest:

Experts on the Management of Diarrhea Associated With EGFR TKIs

Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.

Jonathon B. Cohen, MD

Latest:

Dr Cohen on Available Treatments For MCL

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Jonathon B. Cohen, MD, MS

Latest:

Dr Cohen on Treatment Considerations for Relapsed/Refractory MCL

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

Latest:

Retesting for FLT3 Mutation Status in AML

Jordan Clark, the chief commercial officer at Diaceutics, discusses FLT3 retesting in a relapsed acute myeloid leukemia setting.

Jordan D. Berlin, MD

Latest:

Dr. Berlin on Unmet Needs in Pancreatic Cancer

Jordan D. Berlin, MD, discusses unmet needs in pancreatic cancer.

Jordan Gauthier, MD, MSc

Latest:

Dr. Gauthier on Potential for CAR T Cells in CLL

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Jordan J. Karlitz, MD

Latest:

Despite Benefits, Screening for Lynch Syndrome Often Overlooked

Much work needs to be done to increase Lynch syndrome screening rates and better understand the factors that are associated with low testing rates.

Jordi Bruix, MD

Latest:

Dr. Bruix Discusses Progress of Second-Line Treatment in HCC

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.

Jordi Bruix, MD, Hospital Clinic University of Barcelona

Jordi Giralt, MD, PhD

Latest:

Dr. Giralt on Mucoadhesive Clonidine in Head and Neck Cancer

Jordi Giralt, MD, PhD, pathology, radiology, oncology, University Hospital Vall d'Hebron, discusses a study that examined mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in patients with head and neck cancer.

Jorge A. Garcia, MD

Latest:

Dr. Jorge Garcia on METEOR Trial for RCC

Jorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.

Jorge A. Garcia, MD, FACP, Taussig Cancer Institute

Jorge Cortes, MD

Latest:

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid leukemia, including outcomes related to dose modifications and mutation evolution.

Jorge E. Cortes, MD

Latest:

Emerging Treatment Strategies in Acute Myeloid Leukemia

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.